FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Summary
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.